FDA’s Real-Time Oncology Review (RTOR) program shaved about two months off the average approval time for cancer therapeutics Genentech has submitted through the program, said Grace Gao, regulatory affairs program manager for Hoffmann-La Roche/Genentech, sharing new data at the annual meeting of the Regulatory Affairs Professionals Society in Phoenix this week.
Source: Drug Industry Daily